Immune responses to cancer: are they potential biomarkers of prognosis?
Recent technical improvements in evaluations of immune cells in situ and immune monitoring of patients with cancer have provided a wealth of new data confirming that immune cells play a key role in human cancer progression. This, in turn, has revived the expectation that immune endpoints might serve...
| Egile nagusia: | |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
Frontiers Media S.A.
2013-05-01
|
| Saila: | Frontiers in Oncology |
| Gaiak: | |
| Sarrera elektronikoa: | http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00107/full |
| _version_ | 1828420002084028416 |
|---|---|
| author | Theresa L Whiteside |
| author_facet | Theresa L Whiteside |
| author_sort | Theresa L Whiteside |
| collection | DOAJ |
| description | Recent technical improvements in evaluations of immune cells in situ and immune monitoring of patients with cancer have provided a wealth of new data confirming that immune cells play a key role in human cancer progression. This, in turn, has revived the expectation that immune endpoints might serve as reliable biomarkers of outcome or response to therapy in cancer. The recent successes in linking the T-cell signature in human colorectal carcinoma (CRC) with prognosis have provided a strong motive for searching for additional immune biomarkers that could serve as intermediate endpoints of response to therapy and outcome in human cancers. A number of potentially promising immune biomarkers have emerged, but most remain to be validated. Among them, the B-cell signature, as exemplified by expression of the immunoglobulin G kappa chain (IGKC) in tumor-infiltrating lymphocytes (TIL), has been validated as a biomarker of response to adjuvant therapy and better survival in patients with breast carcinoma and several other types of human solid tumors. Additional immune endpoints are being currently tested as potentially promising biomarkers in cancer. In view of currently growing use of immune cancer therapies, the search for immune biomarkers of prognosis are critically important for identifying patients who would benefit the most from adjuvant immunotherapy. |
| first_indexed | 2024-12-10T15:04:26Z |
| format | Article |
| id | doaj.art-3d901bcedfe34a60b3bfe656fb254ffc |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-10T15:04:26Z |
| publishDate | 2013-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-3d901bcedfe34a60b3bfe656fb254ffc2022-12-22T01:44:06ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2013-05-01310.3389/fonc.2013.0010744414Immune responses to cancer: are they potential biomarkers of prognosis?Theresa L Whiteside0University of Pittsburgh Cancer InstituteRecent technical improvements in evaluations of immune cells in situ and immune monitoring of patients with cancer have provided a wealth of new data confirming that immune cells play a key role in human cancer progression. This, in turn, has revived the expectation that immune endpoints might serve as reliable biomarkers of outcome or response to therapy in cancer. The recent successes in linking the T-cell signature in human colorectal carcinoma (CRC) with prognosis have provided a strong motive for searching for additional immune biomarkers that could serve as intermediate endpoints of response to therapy and outcome in human cancers. A number of potentially promising immune biomarkers have emerged, but most remain to be validated. Among them, the B-cell signature, as exemplified by expression of the immunoglobulin G kappa chain (IGKC) in tumor-infiltrating lymphocytes (TIL), has been validated as a biomarker of response to adjuvant therapy and better survival in patients with breast carcinoma and several other types of human solid tumors. Additional immune endpoints are being currently tested as potentially promising biomarkers in cancer. In view of currently growing use of immune cancer therapies, the search for immune biomarkers of prognosis are critically important for identifying patients who would benefit the most from adjuvant immunotherapy.http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00107/fullImmune SystemCancerprognosisT-cell signatureB-cell signature |
| spellingShingle | Theresa L Whiteside Immune responses to cancer: are they potential biomarkers of prognosis? Frontiers in Oncology Immune System Cancer prognosis T-cell signature B-cell signature |
| title | Immune responses to cancer: are they potential biomarkers of prognosis? |
| title_full | Immune responses to cancer: are they potential biomarkers of prognosis? |
| title_fullStr | Immune responses to cancer: are they potential biomarkers of prognosis? |
| title_full_unstemmed | Immune responses to cancer: are they potential biomarkers of prognosis? |
| title_short | Immune responses to cancer: are they potential biomarkers of prognosis? |
| title_sort | immune responses to cancer are they potential biomarkers of prognosis |
| topic | Immune System Cancer prognosis T-cell signature B-cell signature |
| url | http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00107/full |
| work_keys_str_mv | AT theresalwhiteside immuneresponsestocanceraretheypotentialbiomarkersofprognosis |